Article Sidebar

PDF (Tiếng Việt)
Published: 2024-10-30
Abstract Views: 50
Views PDF (Tiếng Việt): 77
DOI: https://doi.org/10.52163/yhc.v65iCD10.1589
Issue
Vol. 65 No. CĐ10 - Bệnh viện Thống Nhất
Section
Articles
How to Cite
Tâm, N. Đắc N., Kim, T. H., Hồng, N. T. Đại, & Hằng, P. T. . (2024). 6. EVALUATION OF AFATINIB EFFICACY AS FIRST-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS WITH EGFR MUTATIONS AT THONG NHAT HOSPITAL. Vietnam Journal of Community Medicine, 65(CĐ10 - Bệnh viện Thống Nhất). https://doi.org/10.52163/yhc.v65iCD10.1589

6. EVALUATION OF AFATINIB EFFICACY AS FIRST-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS WITH EGFR MUTATIONS AT THONG NHAT HOSPITAL

Nguyen Dac Nhan Tam1, Truong Hoang Kim2, Nguyen Thi Dai Hong1, Pham Thanh Hang1
1 Thong Nhat Hospital
2 University of Health Sciences - Vietnam National University at Ho Chi Minh City

Main Article Content

Abstract

Advanced non-small cell lung cancer (NSCLC) with EGFR (Epidermal Growth Factor Receptor) mutations shows high efficacy with EGFR TKIs (Tyrosine Kinase Inhibitors) in terms of progression-free survival (PFS) and disease control rate (DCR) compared to standard chemotherapy.


Objective: To evaluate the response rate of afatinib in first-line treatment for advanced NSCLC (stage IIIC, IV) with EGFR mutations and its adverse effects.


Methods: A retrospective descriptive study of 16 patients with advanced non-small cell lung cancer with EGFR mutations treated with afatinib as first-line therapy at Thong Nhat Hospital from January 1, 2018 to July 31, 2022.


Results: The average age was 66 years (66.06 ± 12.81), with the oldest patient being 88 years old and the youngest being 45 years old. Female patients accounted for a higher percentage compared to male patients, with rates of 75% and 25%, respectively. The complete response (CR) rate was 12.5%, partial response (PR) was 50%, stable disease (SD) was 31.3%, and progressive disease (PD) was 6.3%. The disease control rate (DCR) was 93.8%, with a median PFS of 23 months and a median overall survival (OS) of 38 months. Common adverse effects included rash (100%), diarrhea (93.8%), paronychia (87.5%), and stomatitis (87.5%). No grade 3 or 4 adverse effects were observed.


Conclusion: Afatinib provides a high response rate in patients with advanced non-small cell lung cancer with EGFR mutations sensitive to TKIs. Adverse effects can be controlled.

Article Details

Keywords

Advanced stage non-small cell lung cancer, EGFR gene mutation, afatinib

References

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. doi: 10.3322/caac.21660.
[2] Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May. 143 (5 Suppl): e142S-e165S.).
[3] Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361: 947- 957.
[4] Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small- cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13: 239-246.
[5] Wu YL, Cheng Y, Zhou X, et al Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation- positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017; 18:1454-1466.
[6] Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUXLung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014; 15: 213-222.
[7] Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013; 31: 3327-3334.
[8] Park K, Tan EH, O’Byrne K, et al. Afatinib versus gefitinib as first -line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, openlabel, randomised controlled trial. Lancet Oncol. 2016; 17: 577-589.
[9] Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUXLung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015; 16: 141-151.
[10] Watanabe S, Minegishi Y, Yoshizawa H, et al. Effectiveness of gefitinib against non- small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q. J Thorac Oncol. 2014; 9: 189-194.
[11] Yang J et al. J Clin Oncol 33, 2015 (suppl; abstr 8073); Schuler M et al., ELCC 2016, #138PD; Hirsh V JCO 34, 2016 (suppl; abstr 9046).
[12] Keunchil Park, Darren Wan-Teck Lim, and James Chih-Hsin Yang J Clin Oncol 36, 2018. First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the ‘real-world’ clinical setting. Abstract nr e21060.
[13] Halmos et all with Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo), Lung Cancer 2019.